Filtered By:
Therapy: Neoadjuvant Therapy

This page shows you your search results in order of relevance.

Order by Relevance | Date

Total 9943 results found since Jan 2013.

Immune Checkpoint Inhibitors in Triple Negative Breast Cancer: The Search for the Optimal Biomarker
Biomark Insights. 2022 Feb 22;17:11772719221078774. doi: 10.1177/11772719221078774. eCollection 2022.ABSTRACTTriple negative breast cancer (TNBC) is a high-risk and aggressive malignancy characterized by the absence of estrogen receptors (ER) and progesterone receptors (PR) on the surface of malignant cells, and by the lack of overexpression of human epidermal growth factor 2 (HER2). It has limited therapeutic options compared to other subtypes of breast cancer. There is now a growing body of evidence on the role of immunotherapy in TNBC, however much of the data from clinical trials is conflicting and thus, challenging fo...
Source: Biomarker Insights - February 28, 2022 Category: General Medicine Authors: Sadaf Qureshi Nancy Chan Mridula George Shridar Ganesan Deborah Toppmeyer Coral Omene Source Type: research

Cocktail without hangover: in search for the optimal chemotherapy in the combined management of non-operable esophageal carcinomas.
CONCLUSIONS: More research is warranted to further increase the therapeutic ratio in non-operable esophageal cancers. PMID: 28375694 [PubMed - as supplied by publisher]
Source: Acta Oncologica - April 4, 2017 Category: Cancer & Oncology Authors: So B, Marcu LG, Olver I, Gowda R, Bezak E Tags: Acta Oncol Source Type: research

Platinum-based chemotherapy for early triple-negative breast cancer
CONCLUSIONS: Platinum-based chemotherapy using carboplatin in the adjuvant or neoadjuvant setting improves long-term outcomes of DFS and OS in early TNBC, with no evidence of differences by subgroup. This was at the cost of more frequent chemotherapy delays and dose reductions, and greater haematological toxicity, though serious adverse events including neuropathy, febrile neutropenia or treatment-related death were not increased. These findings support the use of platinum-based chemotherapy for people with early TNBC. The optimal dose and regimen are not defined by this analysis, but there is a suggestion that similar rel...
Source: Cochrane Database of Systematic Reviews - September 8, 2023 Category: General Medicine Authors: Sofia Re Mason Melina L Willson Sam J Egger Jane Beith Rachel F Dear Annabel Goodwin Source Type: research

Effectiveness and safety of adjuvant chemotherapy compared to neoadjuvant chemotherapy in patients with penile cancer and positive lymph nodes regarding overall survival and free disease survival: a systematic review and meta-analysis
CONCLUSIONS: There were no differences when comparing adjuvant vs. neoadjuvant chemotherapy or adjuvant vs. no intervention chemotherapy. We conclude that progression-free survival had a better response with adjuvant chemotherapy when compared with neoadjuvant therapy. We suggest more studies with adequate design to offer a stronger recommendation.PMID:35307290 | DOI:10.1016/j.urolonc.2022.02.014
Source: Urologic Oncology - March 21, 2022 Category: Urology & Nephrology Authors: Juan Fernando Paz Rojas Carlos A Ballestas Almario Herney Andr és García-Perdomo Source Type: research